CIP
SUPN icon

Cornerstone Investment Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Cornerstone Investment Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Sell
4,929
-239
-5% -$11.5K 0.01% 265
2026
Q1 		$267K Buy
+5,168
New +$263K 0.01% 191

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Cornerstone Investment Partners's SUPN Position: Q2 2026 in Review

Cornerstone Investment Partners reduced its Supernus Pharmaceuticals (SUPN) stake by 4.6% in Q2 2026, selling an estimated $11.5K and leaving 4,929 shares worth $229K. The position accounts for 0.01% of the portfolio, ranked #265.

Cornerstone Investment Partners first reported a position in SUPN in Q1 2026 and has held it in 2 quarters since. The position peaked at $267K in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Cornerstone Investment Partners held 4,929 shares of Supernus Pharmaceuticals worth $229K as of Q2 2026.
  • Cornerstone Investment Partners sold 239 Supernus Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
  • Supernus Pharmaceuticals made up 0.01% of Cornerstone Investment Partners's portfolio in Q2 2026, its #265 holding.
  • Cornerstone Investment Partners first reported a position in Supernus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Cornerstone Investment Partners's Supernus Pharmaceuticals position peaked at $267K in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Cornerstone Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.